A Phase 3 interventional study of lasofoxifene and placebo in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 201 sites in 32 countries. Open to female participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-08-15.
Sponsored by Ligand Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.
Among the 481 studies in Osteoporosis with a site in United States, this one is the 3rd largest by planned enrollment of the 374 interventional ones that give a count, is one of 19 that started in 2001, is one of 70 in phase 3, and was the 88th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Amber Implants B.V. · Sites in United States
Ages 21–85
University of Connecticut · Sites in United States
Ages 45–70 · Women only · Healthy volunteers
Precision IO Group · Sites in United States
Ages 22+
AO Foundation, AO Spine · Sites in United States, Argentina, Brazil and 11 more countries
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 60 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
481 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 93 · Phase 3 78 · Phase 4 61
First in 1985; this study’s year is marked. 19 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,556 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 73 across the 374 interventional studies, 100 across the 97 observational. Of the 405 that completed or were terminated, 154 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 481 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ligand Pharmaceuticals, one of the names counted as Ligand Pharmaceuticals Incorporated. Under that name alone:
Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Ligand Pharmaceuticals Incorporated has 4 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoporosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
| NCT07325578Precision IO GroupU.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | 2027-01 |
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
| NCT07154719Pennington Biomedical Research CenterGLP-1R Actions on Muscle and the Skeleton | 2027-02-01 |
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 481 studies in Osteoporosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
at least 5 years; Screening bone mineral density more than or equal to 2.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.
Exclusion Criteria:
Metabolic bone disease other than osteoporosis; Taking approved medications for osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lasofoxifene
Other: placebo
Drug: lasofoxifene
0.5 mg once per day, orally
placebo
0.25 mg once per day, orally
New morphometric vertebral fractures
Time frame: 3 years
New cases of breast cancer
Time frame: 5 years
New non-vertebral fractures
Time frame: 5 years
All clinical fractures, non-vertebral fractures, BMD, breast cancer, cardiovascular events, and gynecological safety events
Time frame: 3 years
All clinical fractures, new morphometric vertebral fractures, BMD, cardiovascular events, and gynecological safety events
Time frame: 5 years
Showing the first 100 of 201 sites across 32 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2001, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasofoxifene